1. Introduction {#sec1-nutrients-12-01114}
===============

Chronic hepatitis B (CHB), caused by infection by hepatitis B virus (HBV), is a major medical and public health issue worldwide. Roughly 30% of the world's population shows serological evidence of current or past infection. CHB carriers are a high-risk group for developing cirrhosis and hepatocellular carcinoma. Approximately 50% of CHB infected patients die from liver cancer or cirrhosis in Taiwan \[[@B1-nutrients-12-01114]\]. HBV is a partially double-stranded DNA virus with several serological markers: HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, IgM, and IgG \[[@B2-nutrients-12-01114]\]. HBV DNA and HBeAg are used as markers of viral replication in CHB patients \[[@B3-nutrients-12-01114]\]. The main reasons CHB infections cannot be cured at present are associated with the host gene, the degree of immunity, the genotype and variant of the virus, the amount of virus, and other yet unknown causes. The lower the level of HBV before treatment, the higher the liver inflammation index. Consequently, this leads to a lower level of HBs surface antigen and a higher response rate to treatment \[[@B4-nutrients-12-01114]\].

Patients infected with HBV can develop both an innate and an adaptive immune response. HBV infected liver cells secrete interferon γ, α/β and tumor necrosis factor α which inhibit HBV replication. HBV infected liver cells can activate natural killer cells and natural killer T cells (NKT cells) followed by T cells (predominantly cytotoxic T cells) and B cells \[[@B5-nutrients-12-01114]\]. Previous studies have shown that the proportion of CD4^+^ T cells in the blood of patients with CHB will decrease but the proportion of CD8^+^ T cells will increase. The proportion of CD8^+^ T cells is inversely proportional to the serum HBV concentration \[[@B6-nutrients-12-01114]\]. In addition, previous studies have shown that HBV affects host immunity not only in CD4^+^ and CD8^+^ T cells, but also in the number of CD45RO^+^ T cells (memory T cells) \[[@B7-nutrients-12-01114],[@B8-nutrients-12-01114]\]. CD45RA and CD45RO are markers at different stages of lymphoblast differentiation. CD45RA is expressed on the surface of naive T cells and CD45RO is expressed on the surface of memory T cells. Activated CD45RO^+^ T cells release many lymphokines to trigger or maintain an immune response.

The most common functions of vitamin D are to stimulate the absorption of calcium and phosphorus in the gastrointestinal tract and increase bone mineral content and remodeling. It is currently considered to be a steroid hormone and organs and tissues, including pancreas, large intestine, small intestine, muscles and nervous system, with vitamin D receptors can all be regulated \[[@B9-nutrients-12-01114]\]. Currently, vitamin D receptors are widely found in systemic organs and tissues including bone, the immune system, brain, cardiac system and thyroid. Research shows that vitamin D can produce extra-skeletal effects such as inhibiting cancer progression, skin repair, protecting the cardiovascular system, regulating innate and acquired immunity, eliminating viruses and bacteria and treating and preventing autoimmune diseases. Studies have shown that the progression and prognosis of liver disease is correlated to serum vitamin D concentrations \[[@B10-nutrients-12-01114]\]. Vitamin D supplementation for autoimmune liver disease has been shown to have therapeutic effects \[[@B11-nutrients-12-01114],[@B12-nutrients-12-01114]\]. Vitamin D is mainly composed of 25 (OH) D~3~ (vitamin D~3~) in the blood. There is currently no consensus on the standard of vitamin D~3~ deficiency and deficiency in skeletal and non-skeletal functions. The Institute of Medicine of the National Academies (IOM) recommends that the concentration of vitamin D~3~ is greater than 20 ng/mL. The Endocrine Society and International Osteoporosis Foundation (IOF) recommend the concentration of 25 (OH) D3. More than 30 ng/mL is sufficient \[[@B13-nutrients-12-01114]\]. According to the above definition, about 1 billion people in the world are deficient in vitamin D \[[@B14-nutrients-12-01114]\]. Clinical and epidemiological data indicate that chronic viral hepatitis is related to vitamin D concentration \[[@B15-nutrients-12-01114]\]. In hepatitis diseases, the serum vitamin D~3~ concentration of patients with chronic hepatitis C was lower than that of healthy people, and the concentration of vitamin D~3~ in patients with chronic hepatitis C was less than 30 ng/mL (73%). Patients with severe hepatitis C fibrosis have lower vitamin D concentrations than mild fibrosis \[[@B16-nutrients-12-01114]\]. The prevalence of vitamin D~3~ deficiency (\<20 ng/mL) in patients with CHB is as high as 81%. Patients with chronic hepatitis B have lower vitamin D~3~ levels compared to patients with chronic hepatitis C. Vitamin D is an independent factor for the level of hepatitis B virus and serum vitamin D concentration is negatively correlated with serum HBV DNA levels. The serum vitamin D~3~ concentration and the level of HBV DNA are impacted by the season. In the autumn and winter seasons, patients have a lower vitamin D concentration and higher levels of HBV DNA compared to the summer and spring seasons \[[@B17-nutrients-12-01114]\]. Some studies have shown that HBV reduces the expression of vitamin D receptors in HBV-infected cells, reduces vitamin D from aiding the immune defense system, and thus reduces the effect of inhibiting viral replication \[[@B18-nutrients-12-01114],[@B19-nutrients-12-01114]\]. This indicates that vitamin D~3~ affects the immune status of patients by influencing the level of HBV DNA. In turn, the level of HBV DNA influences the efficacy of treatment of hepatitis B \[[@B20-nutrients-12-01114],[@B21-nutrients-12-01114]\].

Furthermore, the chronicity of hepatitis B virus infection has been attributed to the inappropriate functioning of cell-mediated immunity. However, the influences of vitamin D~3~, immune cell and HBeAg status on HBV viral load in CHB patients is still unclear and has not been reported for Taiwan. The objective of this study was to investigate the relationship between serum concentrations of vitamin D, percentage of immune cells in peripheral blood and HBV viral load in CHB patients.

2. Materials and Methods {#sec2-nutrients-12-01114}
========================

2.1. Study Participants Kuang-Tien {#sec2dot1-nutrients-12-01114}
----------------------------------

The patients were enrolled from among the outpatients of General Hospital from May to September 2016. The following were used as the inclusion criteria: chronic hepatitis B carriers, HBeAg-positive or -negative, and ALT less than two times that of the normal value in healthy individuals (\>40 units/L and \<80 units/L). The exclusion criteria diagnosed by a physician were cirrhosis, liver cancer, hepatitis C, diabetes, immune diseases, other malignancies, other chronic diseases, infection, pregnancy, or other systematic immune diseases. A total of 60 CHB patients were enrolled from a Liver Disease Clinic within the hospital located in the mid-coastal region of Taiwan. The study protocol was approved by the ethics committees (KTGH IRB No: 10501), and informed consent was obtained from all study participants. The study was carried out in accordance with the ethics principles of the Declaration of Helsinki and was consistent with good clinical practice guidelines and local regulatory requirements.

2.2. Analysis of Basic and Biochemical Data of Subjects {#sec2dot2-nutrients-12-01114}
-------------------------------------------------------

Demographic data were collected including age, gender, education level, smoking, alcohol drinking, nutrition supplementation, and body mass index (BMI). Blood testing was performed including serum vitamin D~3~ concentrations, blood cell analysis, biochemical tests and HBV DNA levels. Heparinized blood was collected to evaluate liver and kidney function and genotype, and to quantify HBV DNA concentration, HBsAg, anti-HBs, HBeAg, and anti-HBeAg. The remaining blood was segregated into serum and cells. Serum was stored as aliquots in liquid nitrogen until analysis and cells were analyzed to determine the T cell subtypes. Complete blood count (CBC) examinations, including hemoglobin (Hb), white blood cell (WBC) count, neutrophil, lymphocyte, and platelet (PLT), were performed using a Sysmex XE-5000 hematology analyzer (Sysmex Corporation, Kobe, Japan). Total cholesterol, triglyceride, creatinine, and fasting glucose were measured as part of the routine serum biochemistry profile (Beckman Coulter, California, USA). Vitamin D level was measured using chemiluminescence assay. HBsAg level was measured using Chemiluminescent microparticle immunoassay by Architect i2000SR analyzer (Abbott Diagnostic, Chicago, IL, USA). HBV DNA loads were measured by real time polymerase chain reaction (RT-PCR) using the 7500 Fast Real-Time PCR System (Applied Biosystems, California, USA). Liver function tests, including assessment of alanine transaminase (ALT) and aspartate transaminase (AST) enzyme levels, platelet count (PLT), total and direct bilirubin, and albumin, were performed using a Beckman UniCel DxC800 Synchron (Analyzer (Beckman Coulter, California, USA). Total HBsAg, HBeAg, and anti-HBe were determined using Radio-immunoassay Kit and by Elecsys 2010 system (Roche, Mannheim, Germany).

2.3. Analysis of T Cell Subtypes {#sec2dot3-nutrients-12-01114}
--------------------------------

The cells were incubated with fluorescein isothiocyanate (FITC)-conjugated anti-human CD3, anti-human CD25, anti-human CD45RO, or anti-human CD45RO antibodies for 20 min at 4 °C in the dark, followed by staining with phycoerythrin (PE)-conjugated anti-human CD4, anti-human CD8, or CD19 antibodies, for separating individual T cell subtypes. PE-conjugated mouse IgG1 antibodies were used as isotype controls. These antibodies were purchased from BD Company (Franklin Lakes, NJ, USA). T-lymphocyte surface makers (CD3^+^CD4^+^, CD3^+^CD8^+,^ CD4^+^CD45RA^+^, CD4^+^CD45RO^+,^ CD8^+^CD45RA^+^, CD8^+^CD45RO^+^), and B-lymphocyte surface makers (CD19^+,^ CD19^+^CD45RA^+^, CD19^+^CD45RO^+^) in peripheral blood were detected using flow cytometry analysis.

2.4. Statistics {#sec2dot4-nutrients-12-01114}
---------------

Continuous data with normal distribution were presented as mean ± SD and performed by ANOVA; non-normal distribution data were presented as median (IQR) using the Kruskal-Wallis test. Categorical data were presented as *n* (%) using the chi-squared test or Fisher's exact test as appropriate. Correlations between variables were evaluated using the Pearson's correlation test or Spearman's rank correlation test as data with or without normal distribution. After univariate analyses, multivariate analyses were performed for significant associations. Multivariate models were obtained by backward selection, using *p* value \> 0.15 for removal from the model. Only patients with complete data for the remaining covariates were included in multivariate analyses. A two-sided *p*-value \< 0.05 was considered statistically significant. All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA).

3. Results {#sec3-nutrients-12-01114}
==========

3.1. Characteristics of Patients {#sec3dot1-nutrients-12-01114}
--------------------------------

In this study, CHB patients had a mean serum vitamin D~3~ concentration of 20.9 ± 5.6 ng/mL. We categorized the vitamin D~3~ status as normal (≥30 ng/mL), insufficient (20--30 ng/mL) and deficient (\<20 ng/mL). Up to 88.3% of patients were either vitamin D~3~ deficient or insufficient. The gender and body mass index (BMI) significantly correlated to serum vitamin D levels in these CHB patients (*p* = 0.04) ([Table 1](#nutrients-12-01114-t001){ref-type="table"}).

3.2. The Connection Between Hbeag Levels and Vitamin D3 Status {#sec3dot2-nutrients-12-01114}
--------------------------------------------------------------

The relationships between vitamin D~3~ status and various laboratory parameters are shown in [Table 2](#nutrients-12-01114-t002){ref-type="table"}. 89.7% of study participants were HBeAg-negative. Hepatitis B surface antigen (HBsAg) levels are significantly correlated to serum vitamin D~3~ levels in CHB patients (*p* = 0.00). The lower levels of HBeAg were in the normal (≥30 ng/mL) and insufficient (20--30 ng/mL) vitamin D~3~ group. The levels of Hemoglobin (Hb), PLT, Alanine aminotransferase (ALT) and total cholesterol also showed similar trends.

3.3. The Connection Between Immunity and Vitamin D3 Status {#sec3dot3-nutrients-12-01114}
----------------------------------------------------------

[Table 3](#nutrients-12-01114-t003){ref-type="table"} shows the relationship between vitamin D and levels of peripheral immune cells. Study participants in the 3 vitamin D groups had CD19^+^ cell counts of 3.1 ± 2.5, 10.9 ± 5.2, and 8.0 ± 4.1 (%), respectively (*p* = 0.001).

3.4. Factors Associated With HBV DNA Serum Concentration {#sec3dot4-nutrients-12-01114}
--------------------------------------------------------

[Table 4](#nutrients-12-01114-t004){ref-type="table"} shows the factors associated with HBV DNA serum concentration (log10 IU/mL) using univariate models. Serum vitamin D~3~ concentrations, HBeAg status, HBsAg levels, WBC count, and AST showed statistical significance with HBV DNA levels. In T-lymphocyte surface markers, the proportion of CD4^+^, CD8^+^, CD45^+^ cells showed statistical significance with HBV DNA levels. In B-lymphocyte surface markers, the proportion of CD19^+^ cells showed statistical significance with HBV DNA levels.

3.5. Estimates for HBV DNA Serum Concentration Using Multivariate-Adjusted Models {#sec3dot5-nutrients-12-01114}
---------------------------------------------------------------------------------

[Table 5](#nutrients-12-01114-t005){ref-type="table"} shows the results of multivariate-adjusted models. Levels of vitamin D in the deficient and insufficient range, CD8, HBeAg status, and WBC counts were significantly associated with HBV DNA levels (β:1.28, 95% CI:0.17, 2.39; β:1.99, 95% CI:0.88, 3.10; β:0.09, 95% CI:0.04, 0.14; β:−4.1. 95% CI:−5.28,−2.93; β:−0.28, 95% CI:−0.52, −0.05; all *p* \< 0.05).

4. Discussion {#sec4-nutrients-12-01114}
=============

Our results showed that at the vitamin D~3~ deficient and insufficient concentrations, CD8 levels, HBeAg status and WBC counts were significantly associated with HBV DNA levels. This suggests that in the immune tolerance phase of HBeAg-negative chronic HBV infection, vitamin D~3~ may be a modulator of immune function via CD8, CD19 and white blood cells. The results provide supporting evidence that vitamin D~3~ has roles in immune modulation and regulation of inflammation in CHB patients in the immune tolerance phase. We were also first to find out that vitamin D~3~ levels correlate with the levels of lymphocyte subsets, CD8, CD19, in patients with liver disease.

Previous studies have described the factors that influence vitamin D~3~ levels and vitamin D~3~ deficiency. Hoan et al. examined the correlation between vitamin D levels and HBV-DNA loads in 165 CHB patients. They found that vitamin D levels and HBV-DNA were significantly and inversely correlated. Investigation of PLT, ALT, AST, total-bilirubin, direct-bilirubin, albumin, AFP and prothrombin levels showed that they were either weakly correlated or did not correlate with vitamin D~3~ serum levels. Multivariate logistic regression models showed that HBeAg was negatively and independently associated with low vitamin D levels \[[@B22-nutrients-12-01114]\]. In another study, Chan and colleagues enrolled 737 CHB patients and found that 35% had insufficient and 58% had deficient vitamin D~3~ levels. Using univariate analyses, lower vitamin D~3~ levels were found to be significantly associated with age, lower uric acid levels, HBeAg-positive status, lower calcium levels, season of blood draw (winter or autumn) and HBV genotype D. Using multivariate analyses, only HBV genotype, season of blood draw, calcium level and age showed an association \[[@B23-nutrients-12-01114]\].

One recent study reported correlations between vitamin D~3~ levels and the lymphocyte subsets in 8621 elderly patients with age-related diseases including hypertension, cardiovascular disease (CRVD), cerebrovascular disease (CAD) and type 2 diabetes mellitus (T2DM). More than 70% of the patients in each disease group had total a vitamin D concentration of \< 20 ng/mL. In CRVD patients, CD3 and CD19 correlated with 25(OH) vitamin D~3~. In CAD patients, CD8, CD4, CD19 and CD4/CD8 correlated with 25(OH) vitamin D~2~ and CD8 correlated with 25(OH) vitamin D~3~. In T2DM and hypertension patients, CD8, CD3, CD19 and CD4/CD8 correlated with 25(OH) vitamin D~3~. Though there were some correlations between 25(OH) vitamin D~2~ and 25(OH) vitamin D~3~ status and lymphocyte subsets, the results for kidney disease, digestive disease and fracture/osteoporosis groups were insufficient to draw an inference on the effects of serum levels of vitamin D metabolites on these diseases \[[@B24-nutrients-12-01114]\]. We found that vitamin D correlated with the number of CD8 cells, which is consistent with the results of the above studies. In addition, we found that CD19 may be an important lymphocyte subset between vitamin D~3~ and CHB.

CD19 impacts B lymphocyte activation and differentiation through the modulation of B cell receptor signaling. CD19 is important for establishing optimized immune responses by modulating antigen-independent B cell development and immunoglobulin-induced B lymphocyte activation \[[@B25-nutrients-12-01114]\]. Previous studies have shown a relationship between CD19 and hepatitis C, but few studies of CD19 and CHB \[[@B26-nutrients-12-01114],[@B27-nutrients-12-01114],[@B28-nutrients-12-01114],[@B29-nutrients-12-01114]\]. In patients with recurrent miscarriage, the percentage of CD19^+^ B cells was significantly higher in the vitamin D~3~ insufficiency group than in the vitamin D~3~ normal group \[[@B30-nutrients-12-01114]\]. In children with community-acquired pneumonia, the positive CD19^+^ cells in patients with vitamin D deficiency were significantly less than that in patients without vitamin D~3~ deficiency \[[@B31-nutrients-12-01114]\]. We first reported the evidence linking vitamin D level and CD19 in CHB patients. Further mechanistic studies are needed.

While the potential anti-viral effect of vitamin D~3~ has been described, the mechanisms remain unclear. The interplay between viral infections and vitamin D~3~ remains an intriguing concept. The overall effect vitamin D~3~ can have on the immune signature in the context of viral infections is an area of growing interest \[[@B32-nutrients-12-01114]\]. One recent study showed that severe vitamin D~3~ deficiency was associated with treatment non-response, progression to cirrhosis, and liver-related death. Severe vitamin D~3~ deficiency was a prognostic biomarker in autoimmune hepatitis (AIH) \[[@B33-nutrients-12-01114]\]. One human study reporting the predictive value of pre-treatment with vitamin D~3~ on the virologic response in treated CHB patients. Serum 25(OH) vitamin D levels were affected by gender, season, latitude, and genetic variation in vitamin D~3~ metabolism \[[@B34-nutrients-12-01114]\]. One animal study investigated the therapeutic effect of vitamin D~3~ combined with interferon on mice with hepatitis B. The percentage of CD4^+^ and the CD4^+^/CD8^+^ ratio was significantly increased, but the percentage of CD8^+^ was reduced. The proliferation rate of splenic lymphocytes was higher. Higher efficacy was achieved for the treatment of hepatitis B in mice, possibly through increasing the immune level of mice \[[@B35-nutrients-12-01114]\]. However, the effect of vitamin D~3~ supplementation in combination with IFN-RBV based therapy on the virologic response is still unclear. There is currently no approved recommendation for the use of vitamin D~3~ supplementation and vitamin D~3~ analogues as supportive adjuvant treatment regimens in viral hepatitis. Further randomized, placebo-armed studies need to be performed in order to confirm whether supplementation of vitamin D~3~ or vitamin D~3~ analogues improves sustained virologic responses (SVRs) in combination with specific antiviral treatment strategies in HBV infections \[[@B36-nutrients-12-01114]\].

5. Conclusions {#sec5-nutrients-12-01114}
==============

In summary, we found that, in the immune tolerance phase of HBeAg-negative chronic HBV infection, vitamin D may be a modulator of immune function via CD8, CD19 and white blood cells. Future large-scale studies are likely to confirm our findings.
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nutrients-12-01114-t001_Table 1

###### 

Baseline characteristics of patients included in the study.

  Variable                      Number   Vitamin D, ng/mL    *P*                                       
  ----------------------------- -------- ------------------- -------------------- -------------------- ----------
  Age                           60       44.0 ± 11.2         45.5 ± 10.1          52.4 ± 10.1          0.18 ^a^
  BMI (kg/m^2^)                 60       21.9 (20.2--25.7)   25.4 (23.0-- 28.1)   23.1 (20.6-- 23.7)   0.04 ^b^
  Sex                                                                                                  0.04 ^c^
  Male                          35       11 (40.7)           18 (69.2)            6 (85.7)             
  Female                        25       16 (59.3)           8 (30.8)             1 (14.3)             
  Education                                                                                            0.89 ^c^
  Under junior high school      6        3 (11.1)            3 (11.5)             0 (0.0)              
  Senior high school            19       7 (25.9)            9 (34.6)             3 (42.9)             
  Above college                 35       17 (63.0)           14 (53.9)            4 (57.1)             
  Nutrition                                                                                            0.20 ^c^
  No                            35       18 (66.7)           15 (57.7)            2 (28.6)             
  Yes                           25       9 (33.3)            11 (42.3)            5 (71.4)             
  Exercise per-week frequency                                                                          0.18 ^c^
  No                            26       14 (51.9)           10 (38.5)            2 (28.6)             
  1                             15       9 (33.3)            5 (19.2)             1 (14.3)             
  1--3                          9        2 (7.4)             6 (23.1)             1 (14.3)             
  \>3                           10       2 (7.4)             5 (19.2)             3 (42.9)             
  Smoke status                                                                                         0.13 ^c^
  No                            55       26 (96.3)           24 (92.3)            6 (71.4)             
  Yes                           5        1 (3.7)             2 (7.7)              2 (28.6)             
  Drink status                                                                                         0.66 ^d^
  No                            45       19 (70.4)           21 (80.8)            5 (71.4)             
  Yes                           15       8 (29.6)            5 (19.2)             2 (28.6)             

^a^: Data were continuous and presented as mean ± SD using ANOVA; ^b^: Data were continuous and presented as median (IQR) using Kruskal-Wallis test; ^c^: Data were categorical and presented as *n* (%) using Fisher's exact test; ^d^: Data were categorical and presented as *n* (%) using chi-squared test.

nutrients-12-01114-t002_Table 2

###### 

Laboratory data of patients included in the study.

  Variable                 Number   Vitamin D, ng/mL       *P*                                           
  ------------------------ -------- ---------------------- ---------------------- ---------------------- -----------
  HBeAg                                                                                                  0.47 ^c^
  negative                 54       25 (92.6)              22 (84.6)              7 (100)                
  positive                 6        2 (7.4)                4 (15.4)               0 (0)                  
  HBsAg, log10 IU/mL       60       3.0 (1.8--3.2)         3.2 (2.3--3.5)         0 (0--2.4)             0.002 ^b^
  Hemoglobin, g/dL         60       13.6 ± 1.5             14.7 ± 1.2             14.0 ± 1.9             0.02 ^a^
  WBC count, ×10^3^/µL     60       5.6 (4.5--6.5)         5.3 (4.8--6.2)         4.7 (4.0--6.5)         0.74 ^b^
  Platelet, ×10^3^/µL      60       213.0 (192.0--261.0)   202.0 (178.0--244.0)   164.0 (137.0--209.0)   0.04 ^b^
  Lymphocyte, %            60       35.9 ± 6.6             33.4 ± 6.1             29.5 ± 5.7             0.05 ^a^
  Neutrophil, %            60       55.4 ± 7.0             59.0 ± 7.1             60.8 ± 6.0             0.08 ^a^
  Total bilirubin, mg/dL   58       0.8 (0.7--1.0)         1.0 (0.8--1.1)         0.9 (0.7--1.2)         0.15 ^b^
  Albumin, g/dL            58       4.7 (4.5--4.8)         4.9 (4.6--5.0)         4.6 (4.6--4.9)         0.08 ^b^
  AC Sugar, g/dL           56       96.5 (94.0--102.0)     100.0 (96.0--105.0)    101.5 (98.0--105.0)    0.18 ^b^
  ALT, IU/L                60       23.0 (18.0--30.0)      33.0 (26.0--49.0)      21.0 (16.0--24.0)      0.01 ^b^
  AST, IU/L                60       23.0 (21.0--26.0)      26.5 (22.0--31.0)      23.0 (19.0--26.0)      0.26 ^b^
  Triglyceride, mg/dL      60       91.0 (61.0--137.0)     87.0 (66.0--113.0)     59.0 (48.0--71.0)      0.09 ^b^
  Cholesterol, mg/dL       60       180.0 (158.0--208.0)   205.5 (191.0--229.0)   171.0 (145.0--194.0)   0.02 ^b^
  Creatinine, mg/dL        57       0.7 ± 0.2              0.9 ± 0.2              0.9 ± 0.2              0.04 ^a^

^a^: Data were continuous and presented as mean ± SD using ANOVA; ^b^: Data were continuous and presented as median (IQR) using Kruskal-Wallis test; ^c^: Data were categorical and presented as *n* (%) using Fisher's exact test; ^d^: Data were categorical and presented as *n* (%) using chi-squared test.

nutrients-12-01114-t003_Table 3

###### 

T-lymphocyte and B-lymphocyte surface makers.

  Variable                       Number   Vitamin D           *P*                                    
  ------------------------------ -------- ------------------- ------------------- ------------------ -----------
  T-lymphocyte surface markers                                                                       
  CD3                            60       44.4 ± 17.0         44.5 ± 14.0         41.4 ± 23.4        0.90 ^a^
  CD4                            60       13.5 ± 8.5          11.4 ± 6.2          11.1 ± 6.6         0.54 ^a^
  CD3CD4                         60       10.2 (6.2--15.2)    9.2 (5.6--13.8)     11.3 (5.8--16.4)   0.78 ^b^
  CD8                            60       10.9 ± 6.8          8.6 ± 5.9           6.9 ± 7.5          0.25 ^a^
  CD3CD8                         60       10.6 (3.9--13.4)    6.3 (3.1--9.5)      3.9 (0.9--9.3)     0.15 ^b^
  CD45RA                         60       28.6 (19.9--34.9)   31.3 (21.8--36.5)   14.3 (4.9--31.8)   0.26 ^b^
  CD4 CD45RA                     60       3.0 (1.3--4.7)      3.2 (2.2--4.6)      0.5 (0.1--4.1)     0.15 ^b^
  CD45RO                         60       7.3 (4.6--10.4)     8.1 (2.9--11.1)     9.6 (7.9--11.9)    0.58 ^b^
  CD4 CD45RO                     60       5.0 (2.3--8.8)      3.4 (1.4--6.1)      5.4 (4.3--9.4)     0.47 ^b^
  CD25                           60       0.5 (0.3--1.6)      0.5 (0.3--3.3)      0.6 (0.2--1.4)     0.97 ^b^
  CD4CD25                        60       0.2 (0.1--0.5)      0.2 (0.1--0.3)      0.1 (0.0--0.3)     0.40 ^b^
  CD8 CD45RA                     60       5.4 (2.2--8.5)      5.9 (2.7--8.1)      3.6 (0.3--8.3)     0.56 ^b^
  CD8 CD45RO                     60       1.4 (0.8--2.8)      1.0 (0.6--1.7)      1.1 (0.1--2.4)     0.26 ^b^
  B-lymphocyte surface markers                                                                       
  CD19                           49       8.0 ± 4.1           10.9 ± 5.2          3.1 ± 2.5          0.001 ^a^
  CD19 CD45RA                    49       5.4 ± 2.6           7.5 ± 3.7           2.7 ± 2.4          0.004 ^a^
  CD19 CD45RO                    49       0.1 (0.0--0.1)      0.0 (0.0--0.1)      0.0 (0.0--0.6)     0.94 ^b^

^a^: Data with normal distribution were presented as mean ± SD and performed by ANOVA; ^b^: Data with non-normal distribution were presented as median (25--75) and performed by Kruskal-Wallis test.

nutrients-12-01114-t004_Table 4

###### 

Factors associated with HBV DNA serum concentration (log10 IU/mL).

  Variable                       Number   Median (IQR), Mean ± SD, or Correlation Coefficient   *P*
  ------------------------------ -------- ----------------------------------------------------- -------------
  Vitamin D, ng/mL                                                                              0.03 ^b^
  \<20                           27       3.0 (2.4--4.5)                                        
  20--30                         26       3.8 (2.4--5.6)                                        
  ≥30                            7        0 (0--3.1)                                            
  Baseline Characteristic                                                                       
  Age                            60       −0.08                                                 0.56 ^c^
  BMI                            60       −0.16                                                 0.23 ^d^
  Gender                                                                                        0.99 ^b^
  Male                           35       3.3 (1.7--5.0)                                        
  Female                         25       3.1 (2.4--4.1)                                        
  Education                                                                                     0.18 ^b^
  Under junior high school       6        2.8 (2.6--3.5)                                        
  Senior high school             19       4.8 (2.2--5.6)                                        
  Above college                  35       3.1 (1.8--4.5)                                        
  Nutrition                                                                                     0.15 ^b^
  No                             35       3.5 (2.4--5.0)                                        
  Yes                            25       2.8 (1.6--3.7)                                        
  Exercise per-week frequency                                                                   0.88 ^a^
  No                             26       3.8 ± 2.0                                             
  1                              15       3.2 ± 2.0                                             
  1--3                           9        3.2 ± 2.6                                             
  \>3                            10       3.5 ± 2.7                                             
  Smoke status                                                                                  0.16 ^b^
  No                             55       3.3 (2.4--4.8)                                        
  Yes                            5        1.5 (0--3.3)                                          
  Drink status                                                                                  0.74 ^b^
  No                             45       3.3 (2.4--4.8)                                        
  Yes                            15       2.7 (2.0--4.5)                                        
  Laboratory data                                                                               
  HBeAg                                                                                         \<0.001 ^b^
  negative                       54       3.1 (2.0--4.1)                                        
  positive                       6        8.2 (8.0--8.2)                                        
  HBsAg, log10 IU/mL             60       0.60                                                  \<0.001 ^d^
  Hemoglobin, g/dL               60       0.12                                                  0.36 ^d^
  WBC count, ×10^3^/µL           60       −0.35                                                 0.01 ^d^
  Platelet, ×10^3^/µL            60       −0.08                                                 0.54 ^d^
  Lymphocyte, %                  60       0.08                                                  0.53 ^c^
  Neutrophil, %                  60       −0.11                                                 0.41 ^c^
  Total bilirubin, mg/dL         58       0.24                                                  0.07 ^d^
  Albumin, g/dL                  58       −0.21                                                 0.12 ^d^
  AC Sugar, g/dL                 56       0.08                                                  0.58 ^d^
  GPT, IU/L                      60       0.22                                                  0.10 ^d^
  GOP, IU/L                      60       0.30                                                  0.02 ^d^
  Triglyceride, mg/dL            60       −0.15                                                 0.26 ^d^
  Cholesterol, mg/dL             60       0.17                                                  0.19 ^c^
  Creatinine, mg/dL              57       0.03                                                  0.82 ^c^
  T-lymphocyte surface makers                                                                   
  CD3                            60       0.28                                                  0.03 ^c^
  CD4                            60       0.15                                                  0.27 ^c^
  CD3CD4                         60       0.20                                                  0.12 ^d^
  CD8                            60       0.41                                                  0.00 ^d^
  CD3CD8                         60       0.39                                                  0.00 ^d^
  CD45RA                         60       0.34                                                  0.01 ^d^
  CD4 CD45RA                     60       0.33                                                  0.01 ^d^
  CD45RO                         60       0.10                                                  0.43 ^d^
  CD4 CD45RO                     60       0.16                                                  0.23 ^d^
  CD25                           60       0.06                                                  0.64 ^d^
  CD4CD25                        60       0.24                                                  0.07 ^d^
  CD8 CD45RA                     60       0.40                                                  0.00 ^d^
  CD8 CD45RO                     60       0.14                                                  0.29 ^d^
  B-lymphocyte surface markers                                                                  
  CD19                           49       0.33                                                  0.02 ^d^
  CD19 CD45RA                    49       0.36                                                  0.01 ^d^
  CD19 CD45RO                    49       −0.10                                                 0.48 ^d^

^a^: Data were classified into more than 3 groups with normal distribution and presented as mean ± SD of HBV DNA (log10 IU/mL) using ANOVA; ^b^: Data were classified without normal distribution and presented as median (IQR) using Wilcoxon rank-sum test (2 groups) or Kruskal-Wallis test (more than 3 groups); ^c^: Data were continuous with normal distribution and presented as Pearson's correlation coefficient; ^d^: Data were continuous without normal distribution and presented as Spearman's correlation coefficient.
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###### 

Estimates for HBV DNA serum concentration (log10 IU/mL) using multiple linear regression.

  Variable               Estimate    95% CI           SE     *P*
  ---------------------- ----------- ---------------- ------ ----------
  Intercept              6.51        (4.69--8.32)     0.91   \<0.0001
  Vitamin D, ng/mL                                           
  \<20                   1.28        (0.17--2.39)     0.55   0.025
  20--30                 1.99        (0.88--3.10)     0.55   0.001
  ≥30                    reference                           
  CD8                    0.09        (0.04--0.14)     0.03   0.001
  HBeAg                                                      
  negative               −4.11       (−5.28--−2.93)   0.59   \<0.0001
  positive               reference                           
  WBC count, ×10^3^/µL   −0.28       (−0.52--−0.05)   0.12   0.018

CI, Confidence interval; SE, standard error.
